{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:26:20Z","timestamp":1786753580918,"version":"build-2736575974"},"reference-count":84,"publisher":"Oxford University Press (OUP)","issue":"suppl_2","license":[{"start":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","award":["2015PG-IBD005"],"award-info":[{"award-number":["2015PG-IBD005"]}],"id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2015-66379-R"],"award-info":[{"award-number":["SAF2015-66379-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Takeda Development Center Americas, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,22]]},"DOI":"10.1093\/ecco-jcc\/jjy011","type":"journal-article","created":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T20:10:05Z","timestamp":1516997405000},"page":"S633-S640","source":"Crossref","is-referenced-by-count":27,"title":["Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"12","author":[{"given":"Juli\u00e1n","family":"Pan\u00e9s","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"},{"name":"Institut d\u2019investigacions Biom\u00e8diques August Pi i Sunyer, CIBERehd, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azucena","family":"Salas","sequence":"additional","affiliation":[{"name":"Institut d\u2019investigacions Biom\u00e8diques August Pi i Sunyer, CIBERehd, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,8,22]]},"reference":[{"key":"key\n\t\t\t\t20180822100406_CIT0001","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.0105-2896.2005.00285.x","article-title":"Lymphocyte homing to the gut: attraction, adhesion, and commitment","volume":"206","author":"Salmi","year":"2005","journal-title":"Immunol Rev"},{"key":"key\n\t\t\t\t20180822100406_CIT0002","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0092-8674(94)90337-9","article-title":"Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm","volume":"76","author":"Springer","year":"1994","journal-title":"Cell"},{"key":"key\n\t\t\t\t20180822100406_CIT0003","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1074-7613(04)00082-2","article-title":"Rolling adhesion through an extended conformation of integrin \u03b1L\u03b22 and relation to \u03b1 I and \u03b2 I-like domain interaction","volume":"20","author":"Salas","year":"2004","journal-title":"Immunity"},{"key":"key\n\t\t\t\t20180822100406_CIT0004","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1083\/jcb.134.4.1063","article-title":"Sequential regulation of alpha 4 beta 1 and alpha 5 beta 1 integrin avidity by CC chemokines in monocytes: implications for transendothelial chemotaxis","volume":"134","author":"Weber","year":"1996","journal-title":"J Cell Biol"},{"key":"key\n\t\t\t\t20180822100406_CIT0005","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/1074-7613(95)90162-0","article-title":"Distinct roles of L-selectin and integrins alpha 4 beta 7 and LFA-1 in lymphocyte homing to Peyer\u2019s patch-HEV in situ: the multistep model confirmed and refined","volume":"3","author":"Bargatze","year":"1995","journal-title":"Immunity"},{"key":"key\n\t\t\t\t20180822100406_CIT0006","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20180822100406_CIT0007","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1365-3083.1995.tb03709.x","article-title":"Human intestinal B-cell blasts and plasma cells express the mucosal homing receptor integrin alpha 4 beta 7","volume":"42","author":"Farstad","year":"1995","journal-title":"Scand J Immunol"},{"key":"key\n\t\t\t\t20180822100406_CIT0008","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t20180822100406_CIT0009","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1053\/gast.2001.27968","article-title":"Immune cell trafficking in uterus and early life is dominated by the mucosal addressin MAdCAM-1 in humans","volume":"121","author":"Salmi","year":"2001","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180822100406_CIT0010","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/ibd.20501","article-title":"Leukocyte adhesion molecules in animal models of inflammatory bowel disease","volume":"14","author":"Rivera-Nieves","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180822100406_CIT0011","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jlb.66.1.67","article-title":"Intestinal inflammation in adhesion molecule-deficient mice: an assessment of P-selectin alone and in combination with ICAM-1 or E-selectin","volume":"66","author":"McCafferty","year":"1999","journal-title":"J Leukoc Biol"},{"key":"key\n\t\t\t\t20180822100406_CIT0012","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1053\/gast.2001.23252","article-title":"Differential role of selectins in experimental colitis","volume":"120","author":"Sans","year":"2001","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180822100406_CIT0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1189\/jlb.72.1.56","article-title":"The role of P-selectin in experimental colitis as determined by antibody immunoblockade and genetically deficient mice","volume":"72","author":"Gironella","year":"2002","journal-title":"J Leukoc Biol"},{"key":"key\n\t\t\t\t20180822100406_CIT0014","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000051916","article-title":"Role of P-selectin and intercellular adhesion molecule-1 in TNB-induced colitis in rats","volume":"63","author":"Yoshida","year":"2001","journal-title":"Digestion"},{"key":"key\n\t\t\t\t20180822100406_CIT0015","doi-asserted-by":"crossref","first-page":"G1706","DOI":"10.1152\/ajpgi.00573.2006","article-title":"T cell-associated CD18 but not CD62L, ICAM-1, or PSGL-1 is required for the induction of chronic colitis","volume":"292","author":"Ostanin","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"key\n\t\t\t\t20180822100406_CIT0016","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/sj.bjp.0704638","article-title":"Leukocyte rolling is exclusively mediated by P-selectinin colonic venules","volume":"135","author":"Wan","year":"2002","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t20180822100406_CIT0017","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1172\/JCI116575","article-title":"Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody","volume":"92","author":"Podolsky","year":"1993","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20180822100406_CIT0018","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/346425a0","article-title":"Adhesion receptors of the immune system","volume":"346","author":"Springer","year":"1990","journal-title":"Nature"},{"key":"key\n\t\t\t\t20180822100406_CIT0019","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF00917626","article-title":"Prevention and reversal of experimental colitis by a monoclonal antibody which inhibits leukocyte adherence","volume":"16","author":"Wallace","year":"1992","journal-title":"Inflammation"},{"key":"key\n\t\t\t\t20180822100406_CIT0020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2249.1995.tb08363.x","article-title":"Anti-CD11b\/CD18 antibodies reduce inflammation in acute colitis in rats","volume":"101","author":"Palmen","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"key\n\t\t\t\t20180822100406_CIT0021","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3109\/00365529609010353","article-title":"Attenuation of the inflammatory response in an animal colitis model by neutrophil inhibitory factor, a novel beta 2-integrin antagonist","volume":"31","author":"Meenan","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t20180822100406_CIT0022","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/intimm\/dxh378","article-title":"Role of T-cell-associated lymphocyte function-associated antigen-1 in the pathogenesis of experimental colitis","volume":"18","author":"Pavlick","year":"2006","journal-title":"Int Immunol"},{"key":"key\n\t\t\t\t20180822100406_CIT0023","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/labinvest.3700398","article-title":"Regulation of dextran sodium sulfate induced colitis by leukocyte beta 2 integrins","volume":"86","author":"Abdelbaqi","year":"2006","journal-title":"Lab Invest"},{"key":"key\n\t\t\t\t20180822100406_CIT0024","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1440-1746.1998.tb00766.x","article-title":"Effects of the anti-ICAM-1 monoclonal antibody on dextran sodium sulphate-induced colitis in rats","volume":"13","author":"Taniguchi","year":"1998","journal-title":"J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180822100406_CIT0025","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1046\/j.1365-2249.1999.00985.x","article-title":"Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1))","volume":"117","author":"Hamamoto","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"key\n\t\t\t\t20180822100406_CIT0026","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0022-3565(25)10653-8","article-title":"Antibodies to intercellular adhesion molecule-1 ameliorate the inflammatory response in acetic acid-induced inflammatory bowel disease","volume":"274","author":"Wong","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20180822100406_CIT0027","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0022-3565(24)36471-7","article-title":"An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice","volume":"280","author":"Bennett","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20180822100406_CIT0028","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1365-2249.2000.01090.x","article-title":"Intercellular adhesion molecule-1 (ICAM-1) deficiency protects mice against severe forms of experimentally induced colitis","volume":"119","author":"Bendjelloul","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"key\n\t\t\t\t20180822100406_CIT0029","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/labinvest.3780164","article-title":"VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice","volume":"80","author":"Soriano","year":"2000","journal-title":"Lab Invest"},{"key":"key\n\t\t\t\t20180822100406_CIT0030","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0016-5085(99)70070-3","article-title":"VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis","volume":"116","author":"Sans","year":"1999","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180822100406_CIT0031","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1053\/gast.2001.29568","article-title":"Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1\/Yit adoptive transfer model of Crohn\u2019s disease in mice","volume":"121","author":"Burns","year":"2001","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180822100406_CIT0032","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0092-8674(90)90661-W","article-title":"VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4\/fibronectin binding site","volume":"60","author":"Elices","year":"1990","journal-title":"Cell"},{"key":"key\n\t\t\t\t20180822100406_CIT0033","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1053\/gast.1996.v111.pm8898653","article-title":"Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7","volume":"111","author":"Hesterberg","year":"1996","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180822100406_CIT0034","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.4049\/jimmunol.158.5.2099","article-title":"Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells","volume":"158","author":"Picarella","year":"1997","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20180822100406_CIT0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev.med.55.091902.104408","article-title":"Progress in antisense technology","volume":"55","author":"Crooke","year":"2004","journal-title":"Annu Rev Med"},{"key":"key\n\t\t\t\t20180822100406_CIT0036","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0016-5085(98)70418-4","article-title":"A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn\u2019s disease","volume":"114","author":"Yacyshyn","year":"1998","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180822100406_CIT0037","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1053\/gast.2001.24015","article-title":"Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn\u2019s disease","volume":"120","author":"Schreiber","year":"2001","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180822100406_CIT0038","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cgh.2006.11.001","article-title":"A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn\u2019s disease","volume":"5","author":"Yacyshyn","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180822100406_CIT0039","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1136\/gut.2003.036160","article-title":"A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis","volume":"53","author":"van Deventer","year":"2004","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180822100406_CIT0040","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1365-2036.2006.02910.x","article-title":"A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis","volume":"23","author":"van Deventer","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180822100406_CIT0041","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1365-2036.2006.02837.x","article-title":"Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial","volume":"23","author":"Miner","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180822100406_CIT0042","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa030002","article-title":"A novel targeted T-cell modulator, efalizumab, for plaque psoriasis","volume":"349","author":"Lebwohl","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180822100406_CIT0043","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaad.2004.09.029","article-title":"Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial","volume":"52","author":"Leonardi","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t20180822100406_CIT0044","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells","volume":"128","author":"Lowes","year":"2008","journal-title":"J Invest Dermatol"},{"key":"key\n\t\t\t\t20180822100406_CIT0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2310\/7750.2007.00006","article-title":"Efalizumab for the treatment of psoriatic arthritis","volume":"11","author":"Papp","year":"2007","journal-title":"J Cutan Med Surg"},{"key":"key\n\t\t\t\t20180822100406_CIT0046","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2147\/OPTH.S110557","article-title":"Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease","volume":"10","author":"Semba","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"key\n\t\t\t\t20180822100406_CIT0047","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/ICO.0000000000000803","article-title":"Safety of Lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study","volume":"35","author":"Donnenfeld","year":"2016","journal-title":"Cornea"},{"key":"key\n\t\t\t\t20180822100406_CIT0048","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"key":"key\n\t\t\t\t20180822100406_CIT0049","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1212\/WNL.53.3.466","article-title":"The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group","volume":"53","author":"Tubridy","year":"1999","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180822100406_CIT0050","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"St\u00fcve","year":"2006","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20180822100406_CIT0051","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1001\/archneur.65.12.noc80051","article-title":"Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab","volume":"65","author":"del Pilar Martin","year":"2008","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20180822100406_CIT0052","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180822100406_CIT0053","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1586\/14737175.4.4.571","article-title":"Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS","volume":"4","author":"Rudick","year":"2004","journal-title":"Expert Rev Neurother"},{"key":"key\n\t\t\t\t20180822100406_CIT0054","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180822100406_CIT0055","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn\u2019s disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180822100406_CIT0056","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn\u2019s disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180822100406_CIT0057","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1476-5381.2009.00137.x","article-title":"Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody","volume":"157","author":"Pullen","year":"2009","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t20180822100406_CIT0058","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180822100406_CIT0059","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180822100406_CIT0060","first-page":"S598","article-title":"Efficacy and safety of abrilumab (AMG 181\/MEDI 7183) therapy for moderate to severe Crohn\u2019s disease","volume":"152","author":"Sandborn","year":"2017","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180822100406_CIT0061","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1016\/S0016-5085(17)30968-X","article-title":"Efficacy and safety of abrilumab in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomized, double-blind, multiple-dose, placebo-controlled study","volume":"152","author":"Sandborn","year":"2017","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180822100406_CIT0062","doi-asserted-by":"crossref","first-page":"S1193","DOI":"10.1016\/S0016-5085(15)34075-0","article-title":"A randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of anti-MAdCAM antibody PF-00547659 (PF) in patients with moderate to severe ulcerative colitis: results of the TURANDOT study","volume":"148","author":"Reinisch","year":"2015","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180822100406_CIT0063","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(17)30930-3","article-title":"Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"390","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180822100406_CIT0064","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180822100406_CIT0065","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1053\/j.gastro.2015.08.044","article-title":"Safety and efficacy of AJM300, an oral antagonist of \u03b14 integrin, in induction therapy for patients with active ulcerative colitis","volume":"149","author":"Yoshimura","year":"2015","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180822100406_CIT0066","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1053\/j.gastro.2006.08.031","article-title":"Antibody blockade of CCL25\/CCR9 ameliorates early but not late chronic murine ileitis","volume":"131","author":"Rivera-Nieves","year":"2006","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180822100406_CIT0067","first-page":"A157","article-title":"Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory & clinical activity in the treatment of Crohn\u2019s disease","volume":"132","author":"Keshav","year":"2007","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180822100406_CIT0068","doi-asserted-by":"crossref","first-page":"e60094","DOI":"10.1371\/journal.pone.0060094","article-title":"A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn\u2019s disease","volume":"8","author":"Keshav","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180822100406_CIT0069","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/apt.13398","article-title":"Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn\u2019s disease","volume":"42","author":"Feagan","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180822100406_CIT0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.clim.2016.11.008","article-title":"The sphingosine-1-phosphate receptor: a novel therapeutic target for multiple sclerosis and other autoimmune diseases","volume":"175","author":"Mao-Draayer","year":"2017","journal-title":"Clin Immunol"},{"key":"key\n\t\t\t\t20180822100406_CIT0071","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMct1101691","article-title":"Fingolimod for multiple sclerosis","volume":"366","author":"Pelletier","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180822100406_CIT0072","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.4049\/jimmunol.178.4.2458","article-title":"FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells","volume":"178","author":"Daniel","year":"2007","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20180822100406_CIT0073","first-page":"699","article-title":"The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice","volume":"16","author":"Deguchi","year":"2006","journal-title":"Oncol Rep"},{"key":"key\n\t\t\t\t20180822100406_CIT0074","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2009.07.005","article-title":"Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells","volume":"31","author":"Cucak","year":"2009","journal-title":"Immunity"},{"key":"key\n\t\t\t\t20180822100406_CIT0075","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1474-4422(16)00018-1","article-title":"Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Cohen","year":"2016","journal-title":"Lancet Neurol"},{"key":"key\n\t\t\t\t20180822100406_CIT0076","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180822100406_CIT0077","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2036.2009.04209.x","article-title":"Late Crohn\u2019s disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients","volume":"31","author":"Veny","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180822100406_CIT0078","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/gut.2006.116467","article-title":"Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease","volume":"56","author":"Kugathasan","year":"2007","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180822100406_CIT0079","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/gutjnl-2016-311717","article-title":"Drug development in IBD: from novel target identification to early clinical trials","volume":"65","author":"Danese","year":"2016","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180822100406_CIT0080","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180822100406_CIT0081","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180822100406_CIT0082","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/cpt.278","article-title":"Why therapeutic drug monitoring is needed for monoclonal antibodies and how do we implement this","volume":"99","author":"Mould","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180822100406_CIT0083","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/gutjnl-2016-312912","article-title":"Next generation of small molecules in inflammatory bowel disease","volume":"66","author":"Olivera","year":"2017","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180822100406_CIT0084","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0165-5728(95)00120-2","article-title":"Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis","volume":"62","author":"Gordon","year":"1995","journal-title":"J Neuroimmunol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/12\/suppl_2\/S633\/25526376\/jjy011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T01:03:03Z","timestamp":1751245383000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/12\/suppl_2\/S633\/5077920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":84,"journal-issue":{"issue":"suppl_2","published-online":{"date-parts":[[2018,8,22]]},"published-print":{"date-parts":[[2018,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy011","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,8]]}}}